Claims
- 1. A glycerin derivative having the formula (I'), or a pharmacologically acceptable salt thereof: ##STR201## wherein A represents (1) a group of the formula: ##STR202## wherein n is an integer of 0 to 6, and R.sup.1, R.sup.2, and R.sup.3 each independently represent a hydrogen atom or an alkoxy group,
- (2) a group of the formula: ##STR203## wherein m is an integer of 0 to 6, or (3) a group of the formula: ##STR204## wherein p is an integer of 0 to 6; B is an alkyl group or an aryl group; and
- D represents a group of the formula:
- --Y--(CH.sub.2).sub.q --G
- wherein Y is selected from the group consisting of ##STR205## --O--(CH.sub.2).sub.r --NR.sup.7 --, ##STR206## wherein R.sup.4 is an aryl group or --CO--NR.sup.5 R.sup.6, R.sup.5 and R.sup.6 each independently represent a hydrogen atom or a lower alkyl, and R.sup.7 represents an acyl group, and r is an integer of 1 to 3;
- q is an integer of 0 to 3; and
- G is ##STR207## or --.sup.30 NR.sup.9 R.sup.10 R.sup.11 X.sup.-, wherein R.sup.9, R.sup.10, and R.sup.11 may be the same or different and each represents a lower alkyl group and X represents a pharmacologically allowable anion.
- 2. The glycerin derivative or pharmacologically acceptable salt thereof as claimed in claim 1, wherein said pharmacologically acceptable salt is a pyridinium salt in which the nitrogen of the pyridyl group of group G is quaternized.
- 3. The glycerin derivative or a pharmacologically acceptable salt thereof as claimed in claim 1, wherein A is formula (1).
- 4. The glycerin derivative or a pharmacologically acceptable salt thereof as claimed in claim 2, wherein A is formula (1), R.sup.1 and R.sup.3 each are methoxy, R.sup.2 is an alkoxy having 14 to 22 carbon atoms, B is methyl, D is --OCO--NR.sup.4 --(CH.sub.2).sub.q --G, R.sup.4 is o-, m- or p-methoxybenzoyl, q is 1 and said pyridinium salt has the formula: ##STR208## wherein R.sup.8 is a lower alkyl and X is a halogen.
- 5. A pharmaceutical composition which comprises a therapeutically effective amount of the glycerin derivative or a pharmacologically acceptable salt thereof as defined in claim 1 and a pharmacologically acceptable carrier.
Priority Claims (1)
Number |
Date |
Country |
Kind |
63-166386 |
Jul 1988 |
JPX |
|
Parent Case Info
This application is a divisional of application Ser. No. 07/710,089, filed on Jun. 4, 1991, U.S. Pat. No. 5,273,985 which is a divisional application of Ser. No. 07/373,350 filed Jun. 29, 1989, now U.S. Pat. No. 5,037,827, each being hereby incorporated by reference.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4737518 |
Nomura et al. |
Apr 1988 |
|
Foreign Referenced Citations (6)
Number |
Date |
Country |
0147768 |
Dec 1984 |
EPX |
0157609 |
Mar 1985 |
EPX |
0158172 |
Aug 1985 |
EPX |
0243047 |
Dec 1985 |
EPX |
0208932 |
Jun 1986 |
EPX |
1293954 |
Dec 1986 |
JPX |
Non-Patent Literature Citations (2)
Entry |
Barner et al, Chem. Abst. 104-88939n (1986). |
Nomura et al, Chem. Abst. 104-88143y (1986). |
Divisions (2)
|
Number |
Date |
Country |
Parent |
710089 |
Jun 1991 |
|
Parent |
373350 |
Jun 1989 |
|